MA42134A - Conjugués peptides/oligonucléotides - Google Patents
Conjugués peptides/oligonucléotidesInfo
- Publication number
- MA42134A MA42134A MA042134A MA42134A MA42134A MA 42134 A MA42134 A MA 42134A MA 042134 A MA042134 A MA 042134A MA 42134 A MA42134 A MA 42134A MA 42134 A MA42134 A MA 42134A
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- oligonucleotides conjugates
- conjugates
- oligonucleotides
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562163960P | 2015-05-19 | 2015-05-19 | |
| US201662337536P | 2016-05-17 | 2016-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42134A true MA42134A (fr) | 2018-03-28 |
Family
ID=57320822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042134A MA42134A (fr) | 2015-05-19 | 2016-05-19 | Conjugués peptides/oligonucléotides |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10675356B2 (fr) |
| EP (2) | EP3297649B1 (fr) |
| JP (2) | JP6954843B2 (fr) |
| KR (2) | KR20240035901A (fr) |
| CN (2) | CN107921092B (fr) |
| AU (1) | AU2016264471B2 (fr) |
| BR (1) | BR112017024929A2 (fr) |
| CA (1) | CA2986228A1 (fr) |
| DK (1) | DK3297649T5 (fr) |
| ES (1) | ES2964695T3 (fr) |
| FI (1) | FI3297649T3 (fr) |
| HK (1) | HK1252759A1 (fr) |
| HR (1) | HRP20231431T1 (fr) |
| IL (1) | IL255655B (fr) |
| MA (1) | MA42134A (fr) |
| MX (1) | MX2017014806A (fr) |
| NZ (1) | NZ737757A (fr) |
| WO (1) | WO2016187425A1 (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017024929A2 (pt) * | 2015-05-19 | 2018-07-31 | Sarepta Therapeutics, Inc. | conjugados de oligonucleotídeo-peptídeo |
| GB2545898B (en) * | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| CN109757108A (zh) | 2016-07-05 | 2019-05-14 | 比奥马林技术公司 | 具有治疗遗传疾病的改善特征的包含双环支架部分的前体mRNA剪接转换或调节寡核苷酸 |
| CA3049424A1 (fr) * | 2017-01-06 | 2018-07-12 | Avidity Biosciences Llc | Compositions d'acide nucleique-polypeptide et methodes d'induction de saut d'exon |
| KR102279333B1 (ko) | 2017-03-07 | 2021-07-20 | 주식회사 만도 | 차량의 디스플레이 시스템 및 이의 구동 방법 |
| GB2580569B (en) * | 2017-06-28 | 2021-08-18 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| CA3075425A1 (fr) * | 2017-09-22 | 2019-03-28 | Avidity Biosciences, Inc. | Compositions d'acides nucleiques-polypeptides et methodes d'induction de saut d'exon |
| KR20200060496A (ko) | 2017-10-04 | 2020-05-29 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 그의 용도 |
| EP3700537A4 (fr) * | 2017-10-17 | 2021-08-04 | Sarepta Therapeutics, Inc. | Conjugués oligonucléotides-peptides bicycliques |
| KR102623786B1 (ko) | 2017-12-06 | 2024-01-11 | 어비디티 바이오사이언시스 인크. | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 |
| JP7564087B2 (ja) | 2018-07-30 | 2024-10-08 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス送達のための三量体ペプチド |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| WO2020247782A1 (fr) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Compositions d'acide nucléique-polypeptide et utilisations de celles-ci |
| AU2020287880A1 (en) | 2019-06-06 | 2022-01-20 | Avidity Biosciences, Inc. | UNA amidites and uses thereof |
| WO2021132591A1 (fr) | 2019-12-26 | 2021-07-01 | 日本新薬株式会社 | Acide nucléique antisens qui induit le saut de l'exon 50 |
| BR112022017066A2 (pt) | 2020-02-28 | 2022-11-16 | Nippon Shinyaku Co Ltd | Ácido nucleico antissentido indutor de salto do éxon 51 |
| US11555190B2 (en) | 2020-03-19 | 2023-01-17 | Avidity Biosciences, Inc. | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
| EP4314298A1 (fr) * | 2021-04-02 | 2024-02-07 | Avidity Biosciences, Inc. | Conjugué anticorps-oligonucléotide et compositions conjuguées anticorps-peptide-oligonucléotide et méthodes d'induction de saut d'exon |
| KR20240024176A (ko) | 2021-06-23 | 2024-02-23 | 니뽄 신야쿠 가부시키가이샤 | 안티센스 올리고머의 조합 |
| WO2023282346A1 (fr) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | Inhibiteur de précipitation |
| CN118475355A (zh) | 2021-07-08 | 2024-08-09 | 日本新药株式会社 | 肾毒性减轻剂 |
| US20240285547A1 (en) | 2021-07-08 | 2024-08-29 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| WO2023283623A1 (fr) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Complexes ciblant le muscle et formulations de traitement de dystrophinopathies |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2023285700A1 (fr) | 2021-07-16 | 2023-01-19 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Oligonucléotide pour inhiber l'activité de tremblement |
| AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
| TW202346589A (zh) | 2022-03-10 | 2023-12-01 | 日商日本新藥股份有限公司 | 抗病毒反義寡聚物 |
| US12071621B2 (en) | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| AU2023254846A1 (en) | 2022-04-15 | 2024-10-10 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| TW202400187A (zh) | 2022-05-06 | 2024-01-01 | 萊登大學醫院 萊登大學醫學中心 | 寡核苷酸 |
| WO2024069235A2 (fr) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions contenant des oligonucléotides ayant des applications théranostiques |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US6559279B1 (en) * | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
| RU2606627C2 (ru) | 2007-11-15 | 2017-01-10 | Серепта Терапьютикс,Инк. | Способ синтеза морфолиновых олигомеров |
| EP2358864B8 (fr) * | 2008-10-23 | 2017-09-13 | Lumen Bioscience, Inc. | Micro-organismes photosynthétiques modifiés pour la production de triglycérides |
| CN102203253B (zh) * | 2008-10-24 | 2016-04-06 | 萨雷普塔治疗公司 | 用于dmd的多外显子跳跃组合物 |
| US20110269665A1 (en) * | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| ES2574625T3 (es) * | 2009-11-25 | 2016-06-21 | Elitechgroup B.V. | Antagonistas de miARN de oligonucleótido conjugado con aglutinante del surco menor (MGB) |
| NO2513310T3 (fr) * | 2009-12-16 | 2018-03-31 | ||
| RS55610B1 (sr) | 2010-09-30 | 2017-06-30 | Nippon Shinyaku Co Ltd | Derivat morfolino nukleinske kiseline |
| EP2699269A1 (fr) | 2011-04-22 | 2014-02-26 | Prosensa Technologies B.V. | Nouveaux composés pour traiter, retarder et/ou prévenir un trouble génétique humain, tel que la dystrophie myotonique de type 1 (dm1) |
| WO2012150960A1 (fr) * | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Conjugués peptides/oligonucléotides |
| US10066228B2 (en) * | 2011-11-30 | 2018-09-04 | Sarepta Therapeutics, Inc. | Oligonucleotides for treating expanded repeat diseases |
| EP2788488B1 (fr) | 2011-12-08 | 2018-03-21 | Sarepta Therapeutics, Inc. | Procédés pour traiter des laminopathies progéroïdes utilisant des analogues d'oligonucléotide ciblant lmna humain |
| US9920085B2 (en) * | 2012-03-20 | 2018-03-20 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| RU2674600C2 (ru) * | 2012-07-03 | 2018-12-11 | Просенса Текнолоджиз Б.В. | Олигонуклеотид для лечения пациентов с мышечной дистрофией |
| US10111962B2 (en) * | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
| NZ732507A (en) | 2013-03-15 | 2018-08-31 | Sarepta Therapeutics Inc | Improved compositions for treating muscular dystrophy |
| MX2017011004A (es) | 2015-02-27 | 2018-02-09 | Sarepta Therapeutics Inc | Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida. |
| BR112017024929A2 (pt) * | 2015-05-19 | 2018-07-31 | Sarepta Therapeutics, Inc. | conjugados de oligonucleotídeo-peptídeo |
-
2016
- 2016-05-19 BR BR112017024929-4A patent/BR112017024929A2/pt active Search and Examination
- 2016-05-19 EP EP16797300.7A patent/EP3297649B1/fr active Active
- 2016-05-19 CN CN201680041867.9A patent/CN107921092B/zh active Active
- 2016-05-19 MA MA042134A patent/MA42134A/fr unknown
- 2016-05-19 AU AU2016264471A patent/AU2016264471B2/en active Active
- 2016-05-19 JP JP2017560238A patent/JP6954843B2/ja active Active
- 2016-05-19 US US15/574,734 patent/US10675356B2/en active Active
- 2016-05-19 KR KR1020247007058A patent/KR20240035901A/ko active Application Filing
- 2016-05-19 DK DK16797300.7T patent/DK3297649T5/da active
- 2016-05-19 CN CN202210279461.1A patent/CN114681621B/zh active Active
- 2016-05-19 CA CA2986228A patent/CA2986228A1/fr active Pending
- 2016-05-19 KR KR1020177035825A patent/KR102644053B1/ko active IP Right Grant
- 2016-05-19 MX MX2017014806A patent/MX2017014806A/es unknown
- 2016-05-19 HR HRP20231431TT patent/HRP20231431T1/hr unknown
- 2016-05-19 ES ES16797300T patent/ES2964695T3/es active Active
- 2016-05-19 FI FIEP16797300.7T patent/FI3297649T3/fi active
- 2016-05-19 NZ NZ737757A patent/NZ737757A/en unknown
- 2016-05-19 WO PCT/US2016/033276 patent/WO2016187425A1/fr active Application Filing
- 2016-05-19 EP EP23195508.9A patent/EP4306538A3/fr active Pending
-
2017
- 2017-11-14 IL IL255655A patent/IL255655B/en unknown
-
2018
- 2018-09-19 HK HK18112084.2A patent/HK1252759A1/zh unknown
-
2020
- 2020-04-28 US US16/860,292 patent/US11097011B2/en active Active
- 2020-11-05 JP JP2020185083A patent/JP2021011505A/ja active Pending
-
2021
- 2021-08-16 US US17/403,403 patent/US11672871B2/en active Active
-
2023
- 2023-04-06 US US18/296,697 patent/US20230310625A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42134A (fr) | Conjugués peptides/oligonucléotides | |
| DK3579883T3 (da) | Pyrrolobenzodiazepin-antistofkonjugater | |
| DK3268047T3 (da) | Amatoxin/antistof-konjugater | |
| DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
| DK3283625T3 (da) | Nukleasemedieret genomeditering | |
| DK3331869T3 (da) | Muscarinagonister | |
| DK3119885T3 (da) | Antistof-fynomer-konjugater | |
| DK3305788T3 (da) | Janus-kinase-hæmmer | |
| DK3277719T3 (da) | Polypeptider | |
| DK3360890T3 (da) | Genterapi | |
| DK3331528T3 (da) | Muskarinagonister | |
| DK3067559T3 (da) | Inflator | |
| DK3148591T3 (da) | Nanopartikel-lægemiddelkonjugater | |
| DK3331529T3 (da) | Muskarinagonister | |
| DK3310450T3 (da) | Olie-vand-separator | |
| DK3612537T3 (da) | Pyrrolobenzodiazepinkonjugater | |
| EP3355931C0 (fr) | Conjugués de protéines | |
| DK3270930T3 (da) | Præeklampsi | |
| DK3259358T3 (da) | Forøget proteinekspression | |
| DK3362444T3 (da) | Forbindelser | |
| DK3292136T3 (da) | Penicillin-g-acylaser | |
| IL284753A (en) | Oligonucleotide peptide conjugates | |
| DK3544634T3 (da) | MET-antistof-lægemiddelkonjugater | |
| DE112015006486A5 (de) | Inkubationsrinne | |
| DK3274482T3 (da) | Stenborsknop |